Tag: nasdaq:xbit

December 31, 2019

XBiotech Sells Human Antibody to Janssen for US$750 Million

XBiotech announced the closing of the sale of its True Human antibody Bermekimab to Johnson & Johnson's Janssen Biotech.
November 12, 2019

XBiotech Doses First Patient in Clinical Study of Bermekimab

The company is evaluating its IL-1a blocking antibody therapy in patients with moderate-to-severe Atopic Dermatitis (AD).
October 2, 2019

XBiotech Doses First Patient in Clinical Study

The company announced the first patient was enrolled in a clinical study in adults with systemic sclerosis.
December 30, 2018

5 Top Weekly NASDAQ Biotech Stocks: Dova Up 41 Percent

Dova Pharmaceuticals, Sesen Bio, Adaptimmune Therapeutics, Mustang Bio and Equillium were last week's top gainers.
December 12, 2018

XBiotech’s Results from Phase 2 Atopic Dermatitis Study Suggest New Drug to Treat Skin Disease

XBiotech (NASDAQ:XBIT) announced today that its open label, proof of concept, multicenter study using bermekimab to treat patients with moderate...
November 4, 2018

5 Top Weekly NASDAQ Biotech Stocks: Aptose Leads this Week

Aptose Biosciences, Trevena, Curis, Geron and Aveo Pharmaceuticals were last week's top gainers on the NASDAQ Biotechnology Index.
July 10, 2018

XBiotech Announces First Patient in Phase 2 Study Evaluating Subcutaneous MABp1 in Patients with Hidradenitis Suppurativa

XBiotech (NASDAQ:XBIT) announced today that the first patient has been enrolled in its Phase 2 open label, dose escalation clinical...